These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 24895141)

  • 21. Latanoprost. A review of its pharmacological properties, clinical efficacy and tolerability in the management of primary open-angle glaucoma and ocular hypertension.
    Patel SS; Spencer CM
    Drugs Aging; 1996 Nov; 9(5):363-78. PubMed ID: 8922563
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Changes in ocular signs and symptoms in patients switching from bimatoprost-timolol to tafluprost-timolol eye drops: an open-label phase IV study.
    Bourne RRA; Kaarniranta K; Lorenz K; Traverso CE; Vuorinen J; Ropo A
    BMJ Open; 2019 Apr; 9(4):e024129. PubMed ID: 30944129
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Incidence of new coding for dry eye and ocular infection in open-angle glaucoma and ocular hypertension patients treated with prostaglandin analogs: retrospective analysis of three medical/pharmacy claims databases.
    Schwartz GF; Kotak S; Mardekian J; Fain JM
    BMC Ophthalmol; 2011 Jun; 11():14. PubMed ID: 21672240
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mixed treatment comparison and meta-regression of the efficacy and safety of prostaglandin analogues and comparators for primary open-angle glaucoma and ocular hypertension.
    Orme M; Collins S; Dakin H; Kelly S; Loftus J
    Curr Med Res Opin; 2010 Mar; 26(3):511-28. PubMed ID: 20014995
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of the effects of latanoprost, travoprost, and bimatoprost on circadian intraocular pressure in patients with glaucoma or ocular hypertension.
    Orzalesi N; Rossetti L; Bottoli A; Fogagnolo P
    Ophthalmology; 2006 Feb; 113(2):239-46. PubMed ID: 16458092
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Twenty-four hour efficacy with preservative free tafluprost compared with latanoprost in patients with primary open angle glaucoma or ocular hypertension.
    Konstas AG; Quaranta L; Katsanos A; Riva I; Tsai JC; Giannopoulos T; Voudouragkaki IC; Paschalinou E; Floriani I; Haidich AB
    Br J Ophthalmol; 2013 Dec; 97(12):1510-5. PubMed ID: 23681371
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A 4-week, dose-ranging study comparing the efficacy, safety and tolerability of latanoprost 75, 100 and 125 μg/mL to latanoprost 50 μg/mL (xalatan) in the treatment of primary open-angle glaucoma and ocular hypertension.
    Eveleth D; Starita C; Tressler C
    BMC Ophthalmol; 2012 May; 12():9. PubMed ID: 22607109
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A comparative study of a preservative-free latanoprost cationic emulsion (Catioprost) and a BAK-preserved latanoprost solution in animal models.
    Daull P; Buggage R; Lambert G; Faure MO; Serle J; Wang RF; Garrigue JS
    J Ocul Pharmacol Ther; 2012 Oct; 28(5):515-23. PubMed ID: 22671995
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Latanoprost 0.005% test formulation is as effective as Xalatan® in patients with ocular hypertension and primary open-angle glaucoma.
    Allaire C; Dietrich A; Allmeier H; Grundmane I; Mazur-Piotrowska G; Neshev P; Kahle G
    Eur J Ophthalmol; 2012; 22(1):19-27. PubMed ID: 22167539
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of timolol, latanoprost, and dorzolamide on circadian IOP in glaucoma or ocular hypertension.
    Orzalesi N; Rossetti L; Invernizzi T; Bottoli A; Autelitano A
    Invest Ophthalmol Vis Sci; 2000 Aug; 41(9):2566-73. PubMed ID: 10937568
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of latanoprost eye drops for glaucoma treatment: a 1-year study in Japan.
    Suzuki M; Mishima HK; Masuda K; Araie M; Kitazawa Y; Azuma I
    Jpn J Ophthalmol; 2000; 44(1):33-8. PubMed ID: 10698023
    [TBL] [Abstract][Full Text] [Related]  

  • 32. First-line latanoprost therapy in ocular hypertension or open-angle glaucoma patients: a 3-month efficacy analysis stratified by initial intraocular pressure.
    Denis P; Baudouin C; Bron A; Nordmann JP; Renard JP; Rouland JF; Sellem E; Amrane M
    BMC Ophthalmol; 2010 Feb; 10():4. PubMed ID: 20181282
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A comparison of the efficacy and tolerability of brimonidine and latanoprost in adults with open-angle glaucoma or ocular hypertension: a three-month, multicenter, randomized, double-masked, parallel-group trial.
    DuBiner HB; Mroz M; Shapiro AM; Dirks MS;
    Clin Ther; 2001 Dec; 23(12):1969-83. PubMed ID: 11813932
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of SofZia-preserved travoprost and benzalkonium chloride-preserved latanoprost on the ocular surface -- a multicentre randomized single-masked study.
    Aihara M; Oshima H; Araie M;
    Acta Ophthalmol; 2013 Feb; 91(1):e7-e14. PubMed ID: 23241328
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of BAK-preserved latanoprost and polyquad-preserved travoprost on ocular surface parameters in patients with glaucoma and ocular hypertension.
    Muz OE; Dagdelen K; Pirdal T; Guler M
    Int Ophthalmol; 2021 Nov; 41(11):3825-3835. PubMed ID: 34263385
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of newly developed preservative-free latanoprost 0.005% eye drops versus preserved latanoprost 0.005% in open angle glaucoma and ocular hypertension: 12-week results of a randomized, multicenter, controlled phase III trial.
    Kim JM; Sung KR; Lee JW; Kyung H; Rho S; Kim CY
    Int J Ophthalmol; 2021; 14(10):1539-1547. PubMed ID: 34667730
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety evaluation of benzalkonium chloride preserved eye-drops compared with alternatively preserved and preservative-free eye-drops in the treatment of glaucoma: a systematic review and meta-analysis.
    Hedengran A; Steensberg AT; Virgili G; Azuara-Blanco A; Kolko M
    Br J Ophthalmol; 2020 Nov; 104(11):1512-1518. PubMed ID: 32051133
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A 6-week, double-masked, parallel-group study of the efficacy and safety of travoprost 0.004% compared with latanoprost 0:005%/timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension.
    Franks WA; Renard JP; Cunliffe IA; Rojanapongpun P
    Clin Ther; 2006 Mar; 28(3):332-9. PubMed ID: 16750448
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A comparison of latanoprost and timolol in primary open-angle glaucoma and ocular hypertension. A 12-week study.
    Mishima HK; Masuda K; Kitazawa Y; Azuma I; Araie M
    Arch Ophthalmol; 1996 Aug; 114(8):929-32. PubMed ID: 8694726
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A double-masked, randomized clinical trial comparing latanoprost with unoprostone in patients with open-angle glaucoma or ocular hypertension.
    Susanna R; Giampani J; Borges AS; Vessani RM; Jordao ML
    Ophthalmology; 2001 Feb; 108(2):259-63. PubMed ID: 11158796
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.